The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Rhee, Jiyoung ^a   Han, Sae Won ^a   Oh, Do Youn ^a   Kim, Jee Hyun ^b   Im, Seock Ah ^a,c   Han, Wonshik ^a   Park, In Ae ^a   Noh, Dong Young ^a   Bang, Yung Jue ^a,c   Kim, Tae You ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SOUTH KOREA; UNIVERSITY HOSPITAL; BREAST; BREAST TUMOR; CHEMISTRY; KAPLAN MEIER METHOD; KOREA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; KOREA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55949130920     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-307     Document Type: Article

References (34)

1. Ahn SH Clinical characteristics of breast cancer patients in Korea in 2000 Arch Surg 2004, 139(1):27-30. discussion 31 14718270 10.1001/ archsurg.139.1.27
2. Wood WCMH Solin LJ Olopade OI Malignant tumors of the breast Philadelphia: Lippincott Wiliams & Wilkins 7 2005.
3. Perou CM Sorlie T Eisen MB Rijn van de M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Molecular portraits of human breast tumours Nature 2000, 406(6797):747-752. 10.1038/35021093 10963602
4. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB Rijn van de M Jeffrey SS Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001, 98(19):10869-10874. 11553815 10.1073/ pnas.191367098 58566
5. Sorlie T Tibshirani R Parker J Hastie T Marron JS Nobel A Deng S Johnsen H Pesich R Geisler S Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 2003, 100(14):8418-8423. 12829800 10.1073/pnas.0932692100 166244
6. Nielsen TO Hsu FD Jensen K Cheang M Karaca G Hu Z Hernandez-Boussard T Livasy C Cowan D Dressler L Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 2004, 10(16):5367-5374. 15328174 10.1158/ 1078-0432.CCR-04-0220 15328174
7. Livasy CA Karaca G Nanda R Tretiakova MS Olopade OI Moore DT Perou CM Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 2006, 19(2):264-271. 16341146 10.1038/ modpathol.3800528 16341146
8. Bauer KR Brown M Cress RD Parise CA Caggiano V Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry Cancer 2007, 109(9):1721-1728. 17387718 10.1002/cncr.22618 17387718
9. Rakha EA El-Sayed ME Green AR Lee AH Robertson JF Ellis IO Prognostic markers in triple-negative breast cancer Cancer 2007, 109(1):25-32. 17146782 10.1002/cncr.22381 17146782
10. Dent R Trudeau M Pritchard KI Hanna WM Kahn HK Sawka CA Lickley LA Rawlinson E Sun P Narod SA Triple-negative breast cancer: Clinical features and patterns of recurrence Clin Cancer Res 2007, 13(15 Pt 1):4429-4434. 17671126 10.1158/1078-0432.CCR-06-3045 17671126
11. Keam B Im SA Kim HJ Oh DY Kim JH Lee SH Chie EK Han W Kim DW Moon WK Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer BMC Cancer 2007, 7(1):203. 17976237 10.1186/1471-2407-7-203 17976237 2217558
12. Haffty BG Yang Q Reiss M Kearney T Higgins SA Weidhaas J Harris L Hait W Toppmeyer D Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 2006, 24(36):5652-5657. 17116942 10.1200/JCO.2006.06.5664 17116942
13. Cleator S Heller W Coombes RC Triple-negative breast cancer: Therapeutic options Lancet Oncol 2007, 8(3):235-244. 17329194 10.1016/ S1470-2045(07)70074-8 17329194
14. Carey LA Dees EC Sawyer L Gatti L Moore DT Collichio F Ollila DW Sartor CI Graham ML Perou CM The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 2007, 13(8):2329-2334. 17438091 10.1158/1078-0432.CCR-06-1109 17438091
15. Carey LA Perou CM Livasy CA Dressler LG Cowan D Conway K Karaca G Troester MA Tse CK Edmiston S Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 2006, 295(21):2492-2502. 16757721 10.1001/jama.295.21.2492 16757721
16. Kim MJ Ro JY Ahn SH Kim HH Kim SB Gong G Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes Hum Pathol 2006, 37(9):1217-1226. 16938528 10.1016/j.humpath.2006.04.015 16938528
17. Greene FLPD Fleming ID Fritz AG Balch CM Haller DG Morrow M AJCC cancer staging manual New York: Springer 2002.
18. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 1991, 19(5):403-410. 1757079 10.1111/j.1365-2559.1991.tb00229.x 1757079
19. Lee KH Im SA Oh DY Lee SH Chie EK Han W Kim DW Kim TY Park IA Noh DY Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy BMC Cancer 2007, 7:63. 10.1186/ 1471-2407-7-63 17430582 1863427
20. Hsu SM Raine L Fanger H A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies Am J Clin Pathol 1981, 75(5):734-738. 6165237 6165237
21. de la Rochefordiere A Asselain B Campana F Scholl SM Fenton J Vilcoq JR Durand JC Pouillart P Magdelenat H Fourquet A Age as prognostic factor in premenopausal breast carcinoma Lancet 1993, 341(8852):1039-1043. 8096955 10.1016/0140-6736(93)92407-K 8096955
22. Nixon AJ Neuberg D Hayes DF Gelman R Connolly JL Schnitt S Abner A Recht A Vicini F Harris JR Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer J Clin Oncol 1994, 12(5):888-894. 8164038
23. Xiong Q Valero V Kau V Kau SW Taylor S Smith TL Buzdar AU Hortobagyi GN Theriault RL Female patients with breast carcinoma age 30 years and younger have a poor prognosis: The M.D. Anderson Cancer Center experience Cancer 2001, 92(10):2523-2528. 11745185 10.1002/ 1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6 11745185
24. Hamilton A Piccart M The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2 Ann Oncol 2000, 11(6):647-663. 10942052 10.1023/A:1008390429428 10942052
25. Nicholson RI McClelland RA Finlay P Eaton CL Gullick WJ Dixon AR Robertson JF Ellis IO Blamey RW Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity Eur J Cancer 1993, 29A(7):1018-1023. 8098946 10.1016/ S0959-8049(05)80215-1 8098946
26. Romond EH Perez EA Bryant J Suman VJ Geyer CE Jr Davidson NE Tan-Chiu E Martino S Paik S Kaufman PA Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 2005, 353(16):1673-1684. 16236738 10.1056/NEJMoa052122 16236738
27. Piccart-Gebhart MJ Procter M Leyland-Jones B Goldhirsch A Untch M Smith I Gianni L Baselga J Bell R Jackisch C Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 2005, 353(16):1659-1672. 16236737 10.1056/NEJMoa052306 16236737
28. Smith I Procter M Gelber RD Guillaume S Feyereislova A Dowsett M Goldhirsch A Untch M Mariani G Baselga J 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial Lancet 2007, 369(9555):29-36. 17208639 10.1016/ S0140-6736(07)60028-2 17208639
29. Foulkes WD Brunet JS Stefansson IM Straume O Chappuis PO Begin LR Hamel N Goffin JR Wong N Trudel M The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 2004, 64(3):830-835. 14871808 10.1158/0008-5472.CAN-03-2970 14871808
30. Turner N Tutt A Ashworth A Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 2004, 4(10):814-819. 15510162 10.1038/nrc1457 15510162
31. Lakhani SR Reis-Filho JS Fulford L Penault-Llorca F Vijver van der M Parry S Bishop T Benitez J Rivas C Bignon YJ Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 2005, 11(14):5175-5180. 16033833 10.1158/ 1078-0432.CCR-04-2424 16033833
32. Turner NC Reis-Filho JS Russell AM Springall RJ Ryder K Steele D Savage K Gillett CE Schmitt FC Ashworth A BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 2007, 26(14):2126-2132. 17016441 10.1038/sj.onc.1210014 17016441
33. Farmer H McCabe N Lord CJ Tutt AN Johnson DA Richardson TB Santarosa M Dillon KJ Hickson I Knights C Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005, 434(7035):917-921. 15829967 10.1038/nature03445 15829967
34. Turner N Tutt A Ashworth A Targeting the DNA repair defect of BRCA tumours Curr Opin Pharmacol 2005, 5(4):388-393. 15955736 10.1016/ j.coph.2005.03.006 15955736